[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 1991

Effects of Topical Flurbiprofen on the Intraocular Pressure Lowering Effects of Apraclonidine and Timolol

Author Affiliations

From the Glaucoma Services, The Greater Baltimore (Md) Medical Center (Drs Sulewski, Robin, Cummings, and Arkin), and The Wilmer Ophthalmological Institute, The Johns Hopkins Hospital, Baltimore, Md (Drs Sulewski and Robin).

Arch Ophthalmol. 1991;109(6):807-809. doi:10.1001/archopht.1991.01080060071027

• We performed a prospective study that evaluated whether pretreatment with topical flurbiprofen alters the intraocular pressure (IOP) lowering effects of either topical 1% apraclonidine hydrochloride or 0.5% timolol maleate. Eighteen normal volunteers participated in this six-armed, randomized, double-masked, crossover study. All subjects received the first study medication, either bilateral 0.3% flurbiprofen or placebo (its vehicle), every 30 minutes for four applications. They next received the second study medication: either 0.5% timolol maleate (Timoptic), 1% apraclonidine hydrochloride, or placebo in both eyes. We measured IOP before the instillation of the first study medication and the second study medication (baseline), and then at 1, 3, and 6 hours later. All subjects underwent all six treatment arms. Flurbiprofen alone had no effect on IOP. Maximum IOP lowering occurred between 3 and 6 hours after timolol and apraclonidine administration. There was no difference in IOP lowering between timolol- and apraclonidine-treated eyes. Pretreatment with flurbiprofen did not affect the IOP lowering that was obtained with timolol or apraclonidine administration.